Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents

Hanafiah, 2013, Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence, Hepatology, 57, 1333, 10.1002/hep.26141 Shepard, 2005, Global epidemiology of hepatitis C virus infection, Lancet Infect Dis, 5, 558, 10.1016/S1473-3099(05)70216-4 Simmonds, 2005, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 42, 962, 10.1002/hep.20819 Karoney, 2013, Hepatitis C virus (HCV) infection in Africa: a review, Pan Afr Med J, 14, 44 Afdhal, 2004, The natural history of hepatitis C, Semin Liver Dis, 24, 3, 10.1055/s-2004-832922 Maasoumy, 2012, Natural history of acute and chronic hepatitis C, Best Pract Res Clin Gastroenterol, 26, 401, 10.1016/j.bpg.2012.09.009 Craxì, 2011, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, 55, 245, 10.1016/j.jhep.2011.02.023 Yee, 2012, Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office, Am J Gastroenterol, 107, 669, 10.1038/ajg.2012.48 McHutchison, 1998, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group, N Engl J Med, 339, 1485, 10.1056/NEJM199811193392101 Poynard, 1998, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT), Lancet, 352, 1426, 10.1016/S0140-6736(98)07124-4 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 975, 10.1056/NEJMoa020047 Hadziyannis, 2004, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med, 140, 346, 10.7326/0003-4819-140-5-200403020-00010 Ferenci, 2008, Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response, Gastroenterology, 135, 451, 10.1053/j.gastro.2008.04.015 Zeuzem, 2006, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia, J Hepatol, 44, 97, 10.1016/j.jhep.2005.10.003 Mangia, 2005, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3, N Engl J Med, 352, 2609, 10.1056/NEJMoa042608 Diago, 2010, Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40 KD) plus ribavirin, Hepatology, 51, 1897, 10.1002/hep.23531 Katz, 2012, Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients, Cochrane Database Syst Rev, 9, CD008516 Poynard, 2010, Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest), BMC Gastroenterol, 10, 40, 10.1186/1471-230X-10-40 Dieterich, 2009, Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin, J Viral Hepat, 16, 833, 10.1111/j.1365-2893.2009.01218.x Roffi, 2008, Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis, Antivir Ther, 13, 663, 10.1177/135965350801300506 Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 Sherman, 2011, Response-guided telaprevir combination treatment for hepatitis C virus infection, N Engl J Med, 365, 1014, 10.1056/NEJMoa1014463 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Kau, 2008, Treatment predictors of a sustained virologic response in hepatitis B and C, J Hepatol, 49, 634, 10.1016/j.jhep.2008.07.013 Davis, 2010, Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression, Gastroenterology, 138, 513, 10.1053/j.gastro.2009.09.067 Missiha, 2008, Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors, Gastroenterology, 134, 1699, 10.1053/j.gastro.2008.02.069 Doyle, 2012, The role of viral and host genetics in natural history and treatment of chronic HCV infection, Best Pract Res Clin Gastroenterol, 26, 413, 10.1016/j.bpg.2012.09.004 Estrabaud, 2012, Genomics and HCV infection: progression of fibrosis and treatment response, J Hepatol, 57, 1110, 10.1016/j.jhep.2012.05.016 McHutchison, 2002, Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C, Gastroenterology, 123, 1061, 10.1053/gast.2002.35950 Ge, 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, 461, 399, 10.1038/nature08309 Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat Genet, 41, 1105, 10.1038/ng.449 Suppiah, 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy, Nat Genet, 41, 1100, 10.1038/ng.447 Rauch, 2010, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study, Gastroenterology, 138, 1338, 10.1053/j.gastro.2009.12.056 Ank, 2008, An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity, J Immunol, 180, 2474, 10.4049/jimmunol.180.4.2474 Balagopal, 2010, IL28B and the control of hepatitis C virus infection, Gastroenterology, 139, 1865, 10.1053/j.gastro.2010.10.004 Tillmann, 2010, A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice, Gastroenterology, 139, 1586, 10.1053/j.gastro.2010.07.005 Thomas, 2009, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus, Nature, 461, 798, 10.1038/nature08463 Sarrazin, 2011, Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients, J Hepatol, 54, 415, 10.1016/j.jhep.2010.07.041 Thompson, 2010, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus, Gastroenterology, 139, 120, 10.1053/j.gastro.2010.04.013 Ghany, 2011, An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases, Hepatology, 54, 1433, 10.1002/hep.24641 Poordad, 2012, Factors that predict response of patients with hepatitis C virus infection to boceprevir, Gastroenterology, 143, 608, 10.1053/j.gastro.2012.05.011 McGilvray, 2012, Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype, Gastroenterology, 142, 1122, 10.1053/j.gastro.2012.01.028 Urban, 2010, IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C, Hepatology, 52, 1888, 10.1002/hep.23912 Pedersen, 2007, Interferon modulation of cellular microRNAs as an antiviral mechanism, Nature, 449, 919, 10.1038/nature06205 Sarasin-Filipowicz, 2009, Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy, Nat Med, 15, 31, 10.1038/nm.1902 Kato, 2000, Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation, Microb Comp Genomics, 5, 129, 10.1089/omi.1.2000.5.129 Zeisel, 2009, Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy, Front Biosci, 14, 3274, 10.2741/3450 Dammacco, 2012, Mechanisms of cell entry of hepatitis C virus, 63 Ploss, 2012, New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets, Gut, 61, i25, 10.1136/gutjnl-2012-302048 Fehr, 2012, Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases, Cell Cycle, 11, 277, 10.4161/cc.11.2.18699 Kaul, 2009, Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics, PLoS Pathog, 5, e1000546, 10.1371/journal.ppat.1000546 Morikawa, 2011, Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus, J Viral Hepat, 18, 305, 10.1111/j.1365-2893.2011.01451.x Lange, 2013, Perspectives and challenges of interferon-free therapy for chronic hepatitis C, J Hepatol, 58, 583, 10.1016/j.jhep.2012.10.019 Garg, 2011, Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus, Hepatology, 54, 20, 10.1002/hep.24443 Thomas, 2012, Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons, Clin Infect Dis, 54, 979, 10.1093/cid/cir882 Kiser, 2012, Review and management of drug interactions with boceprevir and telaprevir, Hepatology, 55, 1620, 10.1002/hep.25653 Moradpour, 2007, Replication of hepatitis C virus, Nat Rev Microbiol, 5, 453, 10.1038/nrmicro1645 Gish, 2011, The NS5A replication complex inhibitors: difference makers?, Clin Liver Dis, 15, 627, 10.1016/j.cld.2011.05.010 Koch, 2006, Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase, Infect Disord Drug Targets, 6, 31, 10.2174/187152606776056724 Legrand-Abravanel, 2010, New NS5B polymerase inhibitors for hepatitis C, Expert Opin Investig Drugs, 19, 963, 10.1517/13543784.2010.500285 Beaulieu, 2007, Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections, Curr Opin Investig Drugs, 8, 614 Bourliere, 2011, Chronic hepatitis C: treatments of the future, Clin Res Hepatol Gastroenterol, 35, 84, 10.1016/S2210-7401(11)70013-4 Teraoka, 1988, Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus, Transplant Proc, 20, 868 Hopkins, 2012, Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection, Viruses, 4, 2558, 10.3390/v4112558 Hopkins, 2012, The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes, Antimicrobial Agents Chemother, 56, 3888, 10.1128/AAC.00693-12 Guo, 2010, Mammalian microRNAs predominantly act to decrease target mRNA levels, Nature, 466, 835, 10.1038/nature09267 Schaefer, 2012, Anti-hepatitis C virus drugs in development, Gastroenterology, 142, 1340, 10.1053/j.gastro.2012.02.015 Berger, 2009, Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication, Proc Natl Acad Sci U S A, 106, 7577, 10.1073/pnas.0902693106 Ferenci, 2008, Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy, Gastroenterology, 135, 1561, 10.1053/j.gastro.2008.07.072 Kotenko, 2003, IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex, Nat Immunol, 4, 69, 10.1038/ni875 Sheppard, 2003, IL-28, IL-29 and their class II cytokine receptor IL-28R, Nat Immunol, 4, 63, 10.1038/ni873 Gad, 2009, Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family, J Biol Chem, 284, 20869, 10.1074/jbc.M109.002923 Zhang, 2011, IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway, J Hepatol, 55, 289, 10.1016/j.jhep.2010.11.019 Marcello, 2006, Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics, Gastroenterology, 131, 1887, 10.1053/j.gastro.2006.09.052 Kelly, 2011, Interferon lambdas: the next cytokine storm, Gut, 60, 1284, 10.1136/gut.2010.222976 Sommereyns, 2008, IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo, PLoS Pathog, 4, e1000017, 10.1371/journal.ppat.1000017 Muir, 2010, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection, Hepatology, 52, 822, 10.1002/hep.23743 Sulkowski, 2013, Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the sprint-2 trial, Hepatology, 57, 974, 10.1002/hep.26096 Jacobson, 2012, Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin, Hepatology, 56, 567, 10.1002/hep.25865 Bruno, 2013, Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis, J Hepatol, 58, 479, 10.1016/j.jhep.2012.11.020 Foster, 2011, Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections, Gastroenterology, 141, 881, 10.1053/j.gastro.2011.05.046 Fried, 2011, TMC435 in combination with peginterferon and ribavirin in treatmentnaive HCV genotype 1 patients: final analysis of the PILLAR Phase IIb study, Hepatology, 54, 1429A Lenz, 2012, TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial, J Hepatol, 56, S5, 10.1016/S0168-8278(12)60023-3 Sulkowski, 2011, Treatment with the 2nd generation HCV PI BI 201335 results in high and consistent SVR rates-results from SILEN-C1 in treatment naive patients across different baseline factors, Hepatology, 54, 473A Sulkowski, 2011, Sustained viral response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype 1 patients with non-response tp P/R, J Hepatol, 54, S30, 10.1016/S0168-8278(11)60068-8 Dieterich, 2011, SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection, Hepatology, 54, 378A Nettles, 2011, Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1, Hepatology, 54, 1956, 10.1002/hep.24609 Suk-Fong Lok, 2013, HCV NS5A inhibitors in development, Clin Liver Dis, 17, 111, 10.1016/j.cld.2012.09.006 Pol, 2012, Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial, Lancet Infect Dis, 12, 671, 10.1016/S1473-3099(12)70138-X Gerber, 2013, New therapeutic strategies in HCV: polymerase inhibitors, Liver Int, 33, 85, 10.1111/liv.12068 Pockros, 2011, First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis of the JUMP-C trial, J Hepatol, 54, 538, 10.1016/S0168-8278(11)61361-5 Guedj, 2012, Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128), Hepatology, 55, 1030, 10.1002/hep.24788 Lawitz, 2011, Once-daily PSI-7977 plus peg/RBV in treatment-naive patients with HCV GT1: robust end of treatment response rates are sustained post-treatment, Hepatology, 54, 472A Kowdley, 2012, ATOMIC: 97% RVR for PSI-7977 + PEG/RBV × 12 week regimen in HCV GT1: end to response-guided therapy?, J Hepatol, 56, S1 Hassanein, 2012, Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naïve patients with HCV genotype 1, 4, and 6 infection in the ATOMIC Study, Hepatology, 56, 307A Gane, 2013, Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C, N Engl J Med, 368, 34, 10.1056/NEJMoa1208953 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Jacobson, 2013, Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, 1867, 10.1056/NEJMoa1214854 Wagner, 2011, Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients, Hepatology, 54, 50, 10.1002/hep.24342 Lawitz, 2011, A phase 2b trial comparing 24 to 48 weeks of treatment with tegobuvir (GS-9190)/PEG/RV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection, J Hepatol, 54, S181, 10.1016/S0168-8278(11)60447-9 Flisiak, 2011, Once daily alisporivir (Debio025) plus pegIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients, J Hepatol, 54, S2, 10.1016/S0168-8278(11)60006-8 Pawlotsky, 2012, Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study, Hepatology, 56, 309A Muir, 2012, Peginterferon lambda-1a (Lambda) compared to peginterferon alfa-2a (Alfa) in treatment-naïve patients with HCV genotypes (GT) 1 or 4: SVR24. Results from EMERGE phase 2b, Hepatology, 56, 299A Muir, 2012, Peginterferon lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa), Hepatology, 56, 578A Fredlund, 2012, Peginterferon lambda-1a (Lambda) is associated with less autoimmune thyroid disease and serious autoimmune disease than peginterferon alfa-2a (Alfa) when used in combination with ribavirin (RBV) for the treatment of chronic hepatitis C virus infection, Hepatology, 56, 571A Izumi, 2012, First report of peginterferon lambda/ribavirin in combination with either daclatasvir or asunaprevir in HCV genotype 1 Japanese subjects: early sustained virologic response (SVR4) results from the D-LITE Japanese Sub-study, Hepatology, 56, 310A Lok, 2012, Preliminary study of two antiviral agents for hepatitis C genotype 1, N Engl J Med, 366, 216, 10.1056/NEJMoa1104430 Chayama, 2012, Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders, Hepatology, 55, 742, 10.1002/hep.24724 Gane, 2010, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial, Lancet, 376, 1467, 10.1016/S0140-6736(10)61384-0 Gane, 2012, Interferon-free treatment with a combination of meracitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients, J Hepatol, 56, 555, 10.1016/S0168-8278(12)61423-8 Zeuzem, 2011, Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection, Gastroenterology, 141, 2047, 10.1053/j.gastro.2011.08.051 Zeuzem, 2012, SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/−ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of sound C2, J Hepatol, 56, S45, 10.1016/S0168-8278(12)60115-9 Zeuzem, 2012, The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C, Hepatology, 55, 749, 10.1002/hep.24744 Poordad, 2012, 12-week interferon-free regimen of ABT-450/R + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders, J Hepatol, 56, 549, 10.1016/S0168-8278(12)61410-X Lawitz, 2012, A 12-week interferon-free regimen of ABT-450/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment naive HCV IL28B-CC genotype-1 infected subjects, J Hepatol, 56, S7, 10.1016/S0168-8278(12)60027-0 Poordad, 2013, Exploratory study of oral combination antiviral therapy for hepatitis C, N Engl J Med, 368, 45, 10.1056/NEJMoa1208809 Kowdley, 2013, Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− ribavirin in patients with chronic HCV gt1 infection: results from the AVIATOR study, J Hepatol, 58, 2, 10.1016/S0168-8278(13)60005-7 Jacobson, 2012, VX-222, telaprevir and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen, Hepatology, 56, 308A Sulkowski, 2012, Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/− ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3, J Hepatol, 56, 560, 10.1016/S0168-8278(12)61433-0 Sulkowski, 2012, High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results, J Hepatol, 56, 560, 10.1016/S0168-8278(12)61432-9 Pawlotsky, 2003, Hepatitis C virus genetic variability: pathogenic and clinical implications, Clin Liver Dis, 7, 45, 10.1016/S1089-3261(02)00065-X Pawlotsky, 2011, Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus, Hepatology, 53, 1742, 10.1002/hep.24262 Susser, 2011, Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir, J Clin Virol, 52, 321, 10.1016/j.jcv.2011.08.015 Sarrazin, 2010, Resistance to direct antiviral agents in patients with hepatitis C virus infection, Gastroenterology, 138, 447, 10.1053/j.gastro.2009.11.055 Halfon, 2012, Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?, Liver Int, 32, 79, 10.1111/j.1478-3231.2011.02716.x Fridell, 2011, Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations, Hepatology, 54, 1924, 10.1002/hep.24594 Puyang, 2010, Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors, Antimicrobial Agents Chemother, 54, 1981, 10.1128/AAC.01236-09 Sansonno, 2005, Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations, Lancet Infect Dis, 5, 227, 10.1016/S1473-3099(05)70053-0 Lauletta, 2012, Hepatitis C virus infection and mixed cryoglobulinemia, Clin Dev Immunol, 2012, 502156, 10.1155/2012/502156 Sansonno, 1997, Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis, Hepatology, 25, 1237, 10.1002/hep.510250529 Dammacco, 2010, Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study, Blood, 116, 343, 10.1182/blood-2009-10-245878 Saadoun, 2012, Peg-IFNalpha/ribavirin/protease inhibitor combination is highly effective in HCV-mixed cryoglobulinemia vasculitis, Hepatology, 577A Latt, 2012, Hepatitis C virus and its renal manifestations: a review and update, Gastroenterol Hepatol, 8, 434 Charlton, 2011, Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents – a potentially lethal cocktail, Hepatology, 54, 3, 10.1002/hep.24470